Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 10/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27736080 | 0.87 | EGFR (0.53) | EGFR | |
| SCHEMBL6715880 | 0.85 | RARB (0.45) | MRGPRX4TP53SMN1; SMN2RAB9AEGFR | |
| SCHEMBL14865228 | 0.81 | BCL2 (0.69) | NR4A2BCL2MRGPRX4EGFR | |
| SCHEMBL791483 | 0.80 | PTGER1 (0.56) | NR4A2MRGPRX4PTGER1FOLH1 | |
| SCHEMBL30628893 | 0.79 | MRGPRX4 (0.67) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL565902 | 0.79 | MRGPRX4 (0.67) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL792129 | 0.78 | MRGPRX4 (0.48) | NR4A2MRGPRX4RAB9APTGER1EGFR | |
| SCHEMBL1336517 | 0.76 | HTR7 (0.45) | PTGER1 | |
| SCHEMBL406852 | 0.76 | TTR (0.45) | SMN1; SMN2RAB9AEGFR | |
| SCHEMBL23877803 | 0.76 | CFD (0.47) | BCL2PTGER1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | NR4A2 851/4885BCL2 1359/4885MRGPRX4 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.